Request Demo

Last update 08 May 2025

DLL3 x DNA

Last update 08 May 2025

Basic Info

Related Targets

DLL3DNA

Drugs associated with DLL3 x DNA

Rovalpituzumab tesirine

Target

DLL3 x DNA

Mechanism

DLL3 inhibitors [+1]

Active Org.-

Originator Org.

AbbVie, Inc.

Active Indication-

Inactive Indication

Advanced Malignant Solid Neoplasm [+10]

Drug Highest PhaseSuspended

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with DLL3 x DNA

CTR20181229

/ SuspendedPhase 3

一项广泛期小细胞肺癌受试者继一线含铂化疗后以 Rovalpituzumab Tesirine 作维持治疗的随机、双盲、安慰剂对照3期研究（MERU）

[Translation] A randomized, double-blind, placebo-controlled phase 3 study of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (MERU)

主要:评价与安慰剂相比，Rovalpituzumab Tesirine 能否改善完成4个疗程一线含铂化疗（顺铂或卡铂联合伊立替康或依托泊苷）后具有持续临床获益（SD、PR 或CR）的广泛期SCLC受试者的无进展生存期和总生存期。次要:通过确定客观缓解率（ORR）、临床获益率（CBR）和缓解持续时间（DOR），评价Rovalpituzumab Tesirine 的抗肿瘤活性，并使用EORTC QLQ-C30/LC-13问卷评估患者报告结局（PRO）的变化情况。

[Translation]

Primary: To evaluate whether Rovalpituzumab Tesirine can improve progression-free survival and overall survival compared with placebo in subjects with extensive-stage SCLC who have completed 4 cycles of first-line platinum-containing chemotherapy (cisplatin or carboplatin combined with irinotecan or etoposide) and have sustained clinical benefit (SD, PR or CR). Secondary: To evaluate the anti-tumor activity of Rovalpituzumab Tesirine by determining the objective response rate (ORR), clinical benefit rate (CBR) and duration of response (DOR), and to assess changes in patient-reported outcomes (PROs) using the EORTC QLQ-C30/LC-13 questionnaire.

Start Date11 Jan 2019

Sponsor / Collaborator

BSP Pharmaceuticals SpA

[+2]

NCT03543358

/ CompletedPhase 2

A Multicenter, Long-Term, Rollover Extension Study of Rovalpituzumab Tesirine

The purpose of this long-term, extension study is to provide ongoing safety and efficacy follow-up of subjects who participated in a rovalpituzumab tesirine study that has completed the primary analysis and that is closing.

Start Date10 Sep 2018

Sponsor / Collaborator

AbbVie, Inc.

NCT03334487

/ WithdrawnPhase 3

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

A single-arm, open-label study to assess the overall safety of rovalpituzumab tesirine in participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer by evaluating the frequency of high grade (>= Grade 3) select treatment-emergent adverse events (TEAEs).

Start Date15 Mar 2018

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with DLL3 x DNA

100 Translational Medicine associated with DLL3 x DNA

0 Patents (Medical) associated with DLL3 x DNA

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis